Aarti Drugs Ltd - API Prices Bottomed Out
Aarti Drugs reported Q4FY24 results that exceeded our expectations. Revenue, EBITDA, and PAT grew by 2.3%, 22.3%, and 34.4% QoQ, respectively.
44 Views
Aarti Drugs Ltd - Continued Reduction in APIs Prices
Aarti Drugs’ reported Q3FY24 results stood below our expectations, led by continued reduction in API prices across key therepies and elevated key...
152 Views
Aarti Drugs Ltd - Volume Growth Offset by Low Realizations
Aarti Drugs’ reported Q1FY24 results stood below our expectations due to a fall in exports which comprised Formulations (+6%YoY) and Speciality...
181 Views
Axis Research Scorecard Report for Jan 2024
Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.
294 Views
Pharma - Q2FY24 - Earnings Preview
The Pharma companies under our coverage are likely to report aggregate Revenue/EBITDA/PAT growth of 17.4%/23.8%/25.2% YoY in Q2FY24E.
262 Views